Literature DB >> 22112548

The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression.

Nikoletta Dobos1, Erik F J de Vries, Ido P Kema, Konstantinos Patas, Marloes Prins, Ingrid M Nijholt, Rudi A Dierckx, Jakob Korf, Johan A den Boer, Paul G M Luiten, Ulrich L M Eisel.   

Abstract

Indoleamine 2,3-dioxygenase (IDO), an enzyme which is activated by pro-inflammatory cytokines, has been suggested as a potential link between neuroinflammatory processes in neurodegenerative diseases (like Alzheimer's disease) and depression. The present study aimed to determine whether neuroinflammation-induced increased IDO levels in the mammalian brain will lead to depressive-like behavior. Neuroinflammation was initiated in mice by a single intracerebroventricular injection of lipopolysaccharide (LPS). Cerebral inflammation was monitored 1, 2, 3 and 4 days after the injection with small-animal positron emission tomography (PET) using the inflammatory marker [(11)C]-PK11195. In the presence or absence of systemically applied 1-methyl-tryptophan (1-MT), a competitive IDO-inhibitor, we assessed the development of depressive-like behavioral symptoms in parallel with IDO expression and activity. The PK11195 PET signal reached a highly significant peak 3 days after LPS injection, while these animals displayed a significant increase of depressive-like behavior in the forced swim test compared to vehicle-injected animals. These findings were paralleled by a significant increase of IDO in the brainstem, and an increased kynurenine/tryptophan ratio in the serum. Moreover, we report here for the first time, that inhibition of IDO by 1-MT in centrally induced neuroinflammation under experimental conditions can prevent the development of depressive-like behavior.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22112548     DOI: 10.3233/JAD-2011-111097

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  36 in total

Review 1.  In vivo imaging of neuroinflammation in schizophrenia.

Authors:  Ofer Pasternak; Marek Kubicki; Martha E Shenton
Journal:  Schizophr Res       Date:  2015-06-03       Impact factor: 4.939

Review 2.  Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies.

Authors:  Gislaine Z Réus; Karen Jansen; Stephanie Titus; André F Carvalho; Vilma Gabbay; João Quevedo
Journal:  J Psychiatr Res       Date:  2015-05-19       Impact factor: 4.791

3.  Gentiopicroside abrogates lipopolysaccharide-induced depressive-like behavior in mice through tryptophan-degrading pathway.

Authors:  Ya-Ting Deng; Ming-Gao Zhao; Tian-Jiao Xu; Xin-Hua Li
Journal:  Metab Brain Dis       Date:  2018-06-15       Impact factor: 3.584

4.  Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.

Authors:  Ruin Moaddel; Michelle Shardell; Mohammed Khadeer; Jacqueline Lovett; Bashkim Kadriu; Sarangan Ravichandran; Patrick J Morris; Peixiong Yuan; Craig J Thomas; Todd D Gould; Luigi Ferrucci; Carlos A Zarate
Journal:  Psychopharmacology (Berl)       Date:  2018-08-16       Impact factor: 4.530

5.  Exaggerated Increases in Microglia Proliferation, Brain Inflammatory Response and Sickness Behaviour upon Lipopolysaccharide Stimulation in Non-Obese Diabetic Mice.

Authors:  Barry McGuiness; Sinead M Gibney; Wouter Beumer; Marjan A Versnel; Inge Sillaber; Andrew Harkin; Hemmo A Drexhage
Journal:  Neuroimmunomodulation       Date:  2016-08-17       Impact factor: 2.492

6.  Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice.

Authors:  Angela W Corona; Diana M Norden; John P Skendelas; Yan Huang; Jason C O'Connor; Marcus Lawson; Robert Dantzer; Keith W Kelley; Jonathan P Godbout
Journal:  Brain Behav Immun       Date:  2012-08-19       Impact factor: 7.217

7.  Indoleamine-2,3-Dioxygenase/Kynurenine Pathway as a Potential Pharmacological Target to Treat Depression Associated with Diabetes.

Authors:  Isabella Caroline da Silva Dias; Bruno Carabelli; Daniela Kaori Ishii; Helen de Morais; Milene Cristina de Carvalho; Luiz E Rizzo de Souza; Silvio M Zanata; Marcus Lira Brandão; Thiago Mattar Cunha; Anete Curte Ferraz; Joice Maria Cunha; Janaina Menezes Zanoveli
Journal:  Mol Neurobiol       Date:  2015-12-15       Impact factor: 5.590

Review 8.  IDO and TDO as a potential therapeutic target in different types of depression.

Authors:  Yanjie Qin; Nanxi Wang; Xinlin Zhang; Xuemei Han; Xuejia Zhai; Yongning Lu
Journal:  Metab Brain Dis       Date:  2018-07-16       Impact factor: 3.584

9.  Disrupted Tryptophan Metabolism Induced Cognitive Impairment in a Mouse Model of Sepsis-associated Encephalopathy.

Authors:  Rong Gao; Ming-qiang Kan; Shi-gang Wang; Run-hua Yang; Shao-gang Zhang
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

Review 10.  Microglia in depression: current perspectives.

Authors:  Xiaoning Jia; Zhihua Gao; Hailan Hu
Journal:  Sci China Life Sci       Date:  2020-10-14       Impact factor: 6.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.